Overview

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.

Phase:

PHASE1

Details

Lead Sponsor:

Kittika Poonsombudlert

Treatments:

Ascorbic Acid
Azacitidine
Decitabine
venetoclax